Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States
- 4 August 2012
- journal article
- research article
- Published by Elsevier BV in Vaccine
- Vol. 30 (42), 6016-6019
- https://doi.org/10.1016/j.vaccine.2012.07.056
Abstract
No abstract availableThis publication has 23 references indexed in Scilit:
- Post-licensure monitoring of HPV vaccine in the United StatesVaccine, 2010
- Incidence and Costs of Cervical Intraepithelial Neoplasia in a US Commercially Insured PopulationJournal of Lower Genital Tract Disease, 2010
- Factors Influencing Familial Decision-Making Regarding Human Papillomavirus VaccinationJournal of Pediatric Psychology, 2009
- HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and womenCancer, 2008
- Five-year routine cervical cancer screening rates and intervals in a US health planCurrent Medical Research and Opinion, 2008
- Cost analysis of the National Breast and Cervical Cancer Early Detection ProgramCancer, 2007
- Cervical Cancer Screening Rates in the United States and the Potential Impact of Implementation of Screening GuidelinesCA: A Cancer Journal for Clinicians, 2007
- Impact of HPV testing, HPV vaccine development, and changing screening frequency on national Pap test volumeCancer, 2007
- Assessing the Annual Economic Burden of Preventing and Treating Anogenital Human Papillomavirus-Related Disease in the USPharmacoEconomics, 2005
- The health care costs of cervical human papillomavirus–related diseaseAmerican Journal of Obstetrics and Gynecology, 2004